Imunon Inc Stock Analysis

Imunon Stock Analysis Notes

The company has price-to-book (P/B) ratio of 1.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. Imunon Inc recorded a loss per share of 1.91. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 1st of March 2022. Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey. Imunon operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. To learn more about Imunon Inc call Stacy Lindborg at 609 896 9100 or check out https://imunon.com.

Imunon Inc Investment Alerts

Imunon Inc Upcoming and Recent Events

Imunon Largest EPS Surprises

View All Earnings Estimates

Imunon Stock Institutional Investors

Note, although Imunon's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Imunon Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.88 M.

Imunon Profitablity

Management Efficiency

Imunon Inc has return on total asset (ROA) of (0.6708) % which means that it has lost $0.6708 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4812) %, meaning that it created substantial loss on money invested by shareholders. Imunon's management efficiency ratios could be used to measure how well Imunon manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of January 2025, Return On Tangible Assets is likely to drop to -0.84. In addition to that, Return On Capital Employed is likely to grow to -1.24. At this time, Imunon's Total Assets are very stable compared to the past year. As of the 24th of January 2025, Other Current Assets is likely to grow to about 3.1 M, while Non Current Assets Total are likely to drop about 4 M.

Technical Drivers

As of the 24th of January, Imunon retains the Risk Adjusted Performance of 0.0211, downside deviation of 4.1, and Market Risk Adjusted Performance of (0.42). Imunon technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Imunon Inc Price Movement Analysis

Imunon Inc Insider Trading Activities

Imunon Predictive Daily Indicators

Imunon Forecast Models

Imunon's time-series forecasting models are one of many Imunon's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Imunon's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Imunon prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Imunon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Imunon. By using and applying Imunon Stock analysis, traders can create a robust methodology for identifying Imunon entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Imunon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Imunon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Imunon Inc stock analysis indicators help investors evaluate how Imunon stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Imunon shares will generate the highest return on investment. By understating and applying Imunon stock analysis, traders can identify Imunon position entry and exit signals to maximize returns.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.